PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - NYSE:MD - US58502B1061 - Common Stock
16.27 USD
-0.32 (-1.93%)
16.15 USD
-0.12 (-0.74%)
MD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on MD. With these ratings, MD could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
MD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MD has a better Return On Assets (5.23%) than 80.20% of its industry peers.
MD has a better Return On Equity (13.18%) than 81.19% of its industry peers.
With an excellent Return On Invested Capital value of 9.55%, MD belongs to the best of the industry, outperforming 81.19% of the companies in the same industry.
MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.19%.
The last Return On Invested Capital (9.55%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROIC | 9.55% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
MD has a Profit Margin of 5.66%. This is amongst the best in the industry. MD outperforms 81.19% of its industry peers.
MD has a Operating Margin of 10.97%. This is amongst the best in the industry. MD outperforms 80.20% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
MD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MD has more shares outstanding
MD has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.96 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.96, MD is in line with its industry, outperforming 47.52% of the companies in the same industry.
The Debt to FCF ratio of MD is 2.68, which is a good value as it means it would take MD, 2.68 years of fcf income to pay off all of its debts.
MD has a better Debt to FCF ratio (2.68) than 80.20% of its industry peers.
A Debt/Equity ratio of 0.70 indicates that MD is somewhat dependend on debt financing.
The Debt to Equity ratio of MD (0.70) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 1.96 |
ROIC/WACC1.1
WACC8.66%
2.3 Liquidity
A Current Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
MD's Current ratio of 1.80 is fine compared to the rest of the industry. MD outperforms 67.33% of its industry peers.
A Quick Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.80, MD is doing good in the industry, outperforming 68.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.39%, which is quite impressive.
MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -3.08% in the last year.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 3.76% on average per year.
The Revenue is expected to grow by 2.34% on average over the next years.
EPS Next Y23.94%
EPS Next 2Y12.39%
EPS Next 3Y8.67%
EPS Next 5Y3.76%
Revenue Next Year-5.59%
Revenue Next 2Y-1.54%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.99 indicates a reasonable valuation of MD.
Based on the Price/Earnings ratio, MD is valued cheaply inside the industry as 93.07% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.38. MD is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 8.65, which indicates a very decent valuation of MD.
MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 89.11% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.86, MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.99 | ||
| Fwd PE | 8.65 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 87.13% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MD is valued cheaply inside the industry as 96.04% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.24 | ||
| EV/EBITDA | 6.56 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y12.39%
EPS Next 3Y8.67%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
16.27
-0.32 (-1.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.31%
Inst Owner Change1.32%
Ins Owners1.9%
Ins Owner Change8.02%
Market Cap1.42B
Analysts78.75
Price Target16.92 (4%)
Short Float %2.26%
Short Ratio2.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.94%
Min EPS beat(2)21.14%
Max EPS beat(2)32.73%
EPS beat(4)4
Avg EPS beat(4)26.19%
Min EPS beat(4)15.9%
Max EPS beat(4)34.96%
EPS beat(8)6
Avg EPS beat(8)10.2%
EPS beat(12)6
Avg EPS beat(12)3.22%
EPS beat(16)9
Avg EPS beat(16)4.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.44%
Revenue beat(4)1
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-2.84%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)-3.26%
PT rev (3m)-3.26%
EPS NQ rev (1m)-0.68%
EPS NQ rev (3m)5.42%
EPS NY rev (1m)-0.33%
EPS NY rev (3m)10.08%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.99 | ||
| Fwd PE | 8.65 | ||
| P/S | 0.73 | ||
| P/FCF | 6.24 | ||
| P/OCF | 5.79 | ||
| P/B | 1.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.56 |
EPS(TTM)1.81
EY11.12%
EPS(NY)1.88
Fwd EY11.57%
FCF(TTM)2.61
FCFY16.02%
OCF(TTM)2.81
OCFY17.26%
SpS22.29
BVpS9.57
TBVpS-4.8
PEG (NY)0.38
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROCE | 12.09% | ||
| ROIC | 9.55% | ||
| ROICexc | 11.91% | ||
| ROICexgc | 104.6% | ||
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A | ||
| FCFM | 11.7% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 73.88% | ||
| Cap/Sales | 0.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.31% | ||
| Profit Quality | 206.51% | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.96 |
F-Score7
WACC8.66%
ROIC/WACC1.1
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
EPS Next Y23.94%
EPS Next 2Y12.39%
EPS Next 3Y8.67%
EPS Next 5Y3.76%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
Revenue Next Year-5.59%
Revenue Next 2Y-1.54%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
EBIT growth 1Y39.69%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year49.88%
EBIT Next 3Y15.85%
EBIT Next 5YN/A
FCF growth 1Y63.28%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y43.72%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%